Trial Summary:

This study aims to assess the pharmacodynamic effects of LEE011 (ribociclib) in human prostate cancers prior to surgery and indicate whether it has promising activity against prostate cancers, laying the groundwork for more trials using this drug

Supported By:

Cancer Australia

Eligibility:

Men with localised prostate cancer and at least clinical stage T3a Or Gleason score of between 8 and 10 Or Preoperative PSA greater than or equal to 20 ng/ml AND planned for radical prostatectomy 

Registration ID:

ACTRN12618000354280

Participation:

Australia

Australian Lead Group:

This study is a collaboration between the Chris O’Brien Lifehouse, Sydney, Royal Prince Alfred Hospital, Sydney, University of Adelaide, Adelaide, St Vincent’s Hospital, Sydney, and the NHMRC Clinical Trials Centre at the University of Sydney

Status:

Recruiting

Activation Date:

15.11.2018

Chairs:

Prof Lisa Horvath

Contact:

LEEP.study@sydney.edu.au